Hormone Replacement Therapy Market Set to Grow at 6.48% CAGR Through 2030, Driven by Rising Demand
Hormone Replacement Therapy companies working in the market are Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
(Albany, USA) DelveInsight's ' Hormone Replacement Therapy Market Insights, Competitive Landscape, and Market Forecast–2030 ' report provides a comprehensive analysis of the global hormone replacement therapy (HRT) market, focusing on adoption trends, technological advancements, and market dynamics across key regions. The report examines market growth, offering historical and projected market sizes, revenue trends, and key factors driving the demand for HRT in managing hormonal imbalances.
The report highlights the evolving landscape of hormone replacement therapies, exploring advancements in bioidentical hormones, transdermal delivery systems, and combination therapies that improve efficacy and patient compliance. It delves into how these innovations are enhancing treatment outcomes for conditions such as menopause, hypogonadism, thyroid disorders, and growth hormone deficiencies, providing safer and more personalized solutions.
Additionally, the report evaluates the competitive landscape, profiling major players in the global HRT market while spotlighting emerging technologies and novel therapeutic approaches expected to drive future growth. It provides an in-depth review of ongoing clinical developments, regulatory progress, and recent product approvals, making it a vital resource for understanding the rapidly advancing field of hormone replacement therapy.
Some of the key insights of the Hormone Replacement Therapy Market Report:
The hormone replacement therapy market is projected to expand at a CAGR of 6.48% from 2024 to 2030.
North America is estimated to hold a significant revenue share in the Hormone Replacement Therapy market.
In September 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) recognized the favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of locally advanced or metastatic ESCC and G/GEJ cancers with PD-L1 >1%.
In August 2024, the FDA approved Ascendis Pharma's Yorvipath (palopegteriparatide) as a parathyroid hormone replacement therapy for adults with hypoparathyroidism, with the first U.S. supply expected in early 2025.
In June 2024, Mangoceuticals announced the development of proprietary Oral Dissolvable Tablet (ODT) formulations of Enclomiphene Citrate, Pregnenolone, and DHEA to restore hormonal balance and naturally boost testosterone levels in men.
In May 2023, Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval for VEOZAH (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.
In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labor and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorders. This product was the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
Key players in the global Hormone Replacement Therapy market include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F. Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.
Hormone Replacement Therapy Overview
Hormone Replacement Therapy (HRT) is a widely used treatment designed to replenish hormones that naturally decline due to aging or specific medical conditions. It is commonly prescribed for menopause-related symptoms in women, such as hot flashes, osteoporosis, and mood swings, as well as for hypogonadism and testosterone deficiency in men. Additionally, HRT plays a crucial role in managing conditions like hypothyroidism and growth hormone deficiencies. The therapy is available in various forms, including oral tablets, patches, injections, and topical gels, allowing personalized treatment approaches.
Advancements in hormone formulations, including bioidentical and plant-derived hormones, have improved safety and efficacy, addressing concerns related to long-term use. Increasing awareness of hormonal imbalances and their impact on overall health is driving demand for HRT, making it a significant segment in the global healthcare market.
Hormone Replacement Therapy Market Segment Analysis:
The Hormone Replacement Therapy market report offers market segment analysis for the forecast period 2024-2030, segmented into:
Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others)
Hormone Replacement Therapy Market by Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others)
Hormone Replacement Therapy Market by Route of Administration (Oral, Parenteral, and Transdermal)
Hormone Replacement Therapy Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World)
Download the Hormone Replacement Therapy Market Analysis report for key market trends, innovations, and growth drivers.
Hormone Replacement Therapy Market Dynamics
One of the key factors driving the growth of the hormone replacement therapy market is the increasing awareness among women about managing menopausal symptoms. As women age, estrogen and progesterone levels decline significantly, leading to hormonal imbalances. In response, the pituitary gland increases follicle-stimulating hormone (FSH) production, causing symptoms such as hot flashes, excessive sweating, and palpitations. With a growing global population of women reaching menopause, the demand for hormone replacement therapy to manage these symptoms is expected to rise.
Additionally, ongoing research and development efforts by key pharmaceutical companies are driving the discovery of novel treatments for hormonal imbalances. The increasing number of product approvals is further expanding the availability of hormone replacement therapies. Several companies are actively investing in the introduction of innovative therapies for conditions such as growth hormone deficiency and testosterone replacement, enhancing treatment options for both men and women.
However, certain challenges may hinder market growth. The high costs associated with drug development, potential side effects linked to long-term hormone therapy use, and stringent regulatory approval processes remain significant barriers. Despite these challenges, the overall hormone replacement therapy market is expected to expand steadily, driven by advancements in treatment options and increasing patient awareness.
North America Set to Lead the Growth of the Global Hormone Replacement Therapy Market
North America is expected to dominate the hormone replacement therapy market, driven by the increasing demand for hormone replacement drugs among women due to the rising prevalence of menopausal-related issues. Additionally, the growing incidence of growth deficiencies, thyroid disorders, osteoporosis, and hypogonadism, along with active research and development efforts, is fueling market expansion in the region.
The presence of key pharmaceutical companies, frequent product launches, and favorable reimbursement policies further support market growth. For instance, the increasing prevalence of thyroid-related conditions has led to a higher demand for hormone therapies, as these treatments play a crucial role in managing conditions like thyroid cancer and hormonal imbalances. Moreover, recent product relaunches and strategic collaborations among manufacturers are strengthening the market landscape.
With these factors in play, North America is expected to maintain its leadership in the hormone replacement therapy market throughout the forecast period.
Hormone Replacement Therapy Market Drivers
Growing awareness of menopause-related health issues and a rising aging population are increasing the demand for HRT to manage symptoms like osteoporosis, cardiovascular risks, and hormonal imbalances.
The development of safer, more effective hormone formulations, including bioidentical and plant-based options, has improved patient outcomes and increased adoption rates.
Hormone Replacement Therapy Market Barriers
Concerns about long-term HRT use, including increased risks of breast cancer, cardiovascular diseases, and stroke, limit patient adoption and regulatory approvals.
The cost of HRT, especially newer formulations and customized therapies, can be a financial burden for patients, with limited insurance reimbursement restricting accessibility.
To learn more about Hormone Replacement Therapy drivers and barriers, visit @ Hormone Replacement Therapy Competitive Landscape and Market Forecast Report
Table of Contents
1. Hormone Replacement Therapy Market Report Introduction
2. Hormone Replacement Therapy Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Hormone Replacement Therapy Market Key Factors Analysis
6. Hormone Replacement Therapy Market Porter's Five Forces Analysis
7. Hormone Replacement Therapy Market Layout
8. Hormone Replacement Therapy Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
27 minutes ago
- National Post
Canadian military personnel to get 20% pay hike: defence minister
Canadian Forces personnel are to receive a 20 per cent salary increase, Defence Minister David McGuinty has confirmed. Article content The move is part of a $9-billion spending increase that will see Canada's defence and security budget climb to an all-time high of $62.7 billion annually by next year. The initiative was announced June 9 by Prime Minister Mark Carney. Article content Carney said the salary increases were well deserved and would contribute to retaining personnel in the ranks as well as attracting new recruits. Article content Article content McGuinty told journalists on June 10 that improvements were also coming in military benefits, housing and health care. 'That's where a lot of the initial investment will be, of course, including a 20-per-cent pay increase,' he said. Article content Article content But when that pay hike will come is still unclear. The Ottawa Citizen asked the Department of National Defence on June 10 for details about the raises and for information on when military personnel would see the extra money on their paycheques. DND did not respond. Article content In addition, there will be increases in training allowances and the introduction of retention bonuses for key military personnel. No further details were provided. Article content At a June 9 technical briefing that followed Carney's spending announcement, government officials noted it was expected that around 1,400 new staff would be hired at DND. More health-care workers will be hired for the Canadian Forces and the civilian workforce will be expanded so military personnel can focus on operations, government officials said at the technical briefing. Under government-imposed rules, the officials who provided the briefing cannot be identified. Article content Article content The Ottawa Citizen asked DND on June 9 for a timeline on when the additional 1,400 staff would be hired. DND did not respond. Article content Article content June Winger, national president of the Union of National Defence Employees, said Wednesday that she had received initial information from DND that more civilian staff would be hired, but no specific details. But Winger noted that the department had faced significant barriers in getting new staff in place because of delays in completing security clearances. Such clearances are taking months and perspective staff, instead of waiting, are instead accepting jobs other than at DND, she said. Article content In January, the Ottawa Citizen reported that military staff were recommending retention bonuses to keep key personnel from leaving the ranks, but there were questions at the time about whether the government would fund such a plan.
Globe and Mail
31 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Intel, NVIDIA, Taiwan Semiconductor Manufacturing and Advanced Micro Devices
For Immediate Release Chicago, IL – June 12, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intel Corp. INTC, NVIDIA Corp. NVDA, Taiwan Semiconductor Manufacturing Co. Ltd. TSM and Advanced Micro Devices, Inc.'s AMD. Here are highlights from Wednesday's Analyst Blog: Is Intel the Turnaround Stock of 2025 and a Buy Now? Intel Corp. stock plunged 70% post chip foundry venture, yet Lip-Bu Tan's appointment as new CEO and recent 10% stock rise hint at a potential turnaround. Is it a good buy now? Let's see. Intel May Rebound in 2025 for Four Key Reasons Both Intel and NVIDIA Corp. produce graphics processing units (GPUs) that are essential for modern computing, including machine learning and artificial intelligence (AI). However, NVIDIA's CUDA software and Blackwell chips are highly sought after by developers and customers. The superior products from NVIDIA have allowed the company to secure a substantial share in most major AI segments, including data centers (read more: Is NVIDIA's Rise in Value a Sign to Invest in NVDA Stock?). Of course, it's challenging for Intel to compete with NVIDIA, but the former has more room to grow with a market capitalization of under $100 billion compared to NVIDIA's $3 trillion plus. Moreover, Intel's affordable AI accelerators can rival NVIDIA's. Intel is spending billions of dollars on enhancing its AI capabilities and may enter the market with energy-efficient chips. In the last two years, Intel has spent over $50 billion on upgrading its chip-manufacturing facilities. Such staggering infrastructure costs have made investors nervous due to the unprofitable foundry business. Intel's foundry business continues to face tough competition from the likes of Taiwan Semiconductor Manufacturing Co. Ltd., or TSMC, and Samsung. However, TSMC and Samsung located in Southeast Asia, have manufacturing centers in China. The ongoing trade tensions between the United States and China could disrupt their business. In contrast, Intel's chip-making hubs are primarily in the United States, allowing domestic semiconductor companies to send chip orders to these facilities and bypass trade restrictions. Despite losing the top semiconductor title, Intel generated revenues of $12.7 billion in the first quarter of 2025, outpacing arch-rival Advanced Micro Devices, Inc.'s $7.4 billion. This serves as a clear indication that Intel is making strides in the semiconductor industry and is well-positioned for a comeback. Last but not least, Lip-Bu Tan's appointment as the CEO of Intel has been well-received by market pundits, as his stint in the semiconductor industry has been productive. Tan's initiatives to streamline operations, deliver a competitive AI platform, and spin-off assets would restore stability at Intel and help the company return to its past glory. Is Intel Stock Worth Buying Now? With Lip-Bu Tan leading Intel's foundry recovery and AI accelerators gaining ground among competitors through cost advantages, holding onto INTC stock seems judicious. Intel's business revival is becoming more probable, and brokers are showing optimism by increasing the short-term price target for INTC to $22.42 (up 9.5%) from $20.48. The highest target is $62, indicating a potential 202.7% upside. However, Intel's net profit margin is negative at 36.2%, while the Semiconductor - General industries have a margin of 49.5%, suggesting financial instability due to expenses surpassing revenues. Therefore, new entrants, for now, should wait for improved financials before considering INTC stock. Intel has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report
Globe and Mail
31 minutes ago
- Globe and Mail
The Zacks Analyst Blog Highlights Tesla, Alphabet and Baidu
For Immediate Release Chicago, IL – June 12, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Tesla's TSLA, Alphabet GOOGL and Baidu BIDU. Here are highlights from Wednesday's Analyst Blog: Tesla's Robotaxi Launch Is Almost Here. Can It Really Deliver? Tesla 's long-awaited robotaxi service is finally nearing its launch, which is tentatively set for June 22. Yesterday, CEO Elon Musk reposted a video on X showing a driverless Tesla navigating the streets of Austin, TX, sparking fresh excitement among investors. The video featured a Model Y making turns without a human driver, hinting that Tesla's robotaxi ambitions may be finally coming to life. When asked about the launch date, Musk replied that Tesla plans to start public rides with its robotaxis on June 22. This would mark the first time Tesla offers fully self-driving rides to customers. Musk added that the first trip from the Tesla factory to a customer's house is scheduled for his birthday on June 28. However, he also cautioned that safety remains the top priority, and the timeline could still shift if needed. The initial rollout won't be massive — at least not yet. Tesla plans to start small, with about 10-20 Model Y SUVs giving rides around Austin. For now, there will still be remote human supervision to make sure everything runs smoothly. If everything goes well, Tesla would expand to other states like California, though tougher regulations there might slow things down. Tesla's been busy testing these cars on Austin's streets, using its latest Full Self-Driving software. The video Musk shared showed a Model Y, clearly labeled "Robotaxi," smoothly navigating an intersection on its own with no driver in sight. Musk has bet heavily on self-driving technology as the future of Tesla. The company sees robotaxis as a potential game-changing revenue stream, especially as competition heats up in the core EV market. If Tesla can successfully pull this off, it could be a huge breakthrough for both the company and the broader autonomous driving industry. But as always with Tesla, investors may want to keep expectations in check. Challenges around safety, regulation and the complexity of full autonomy still loom large. TSLA Still a Laggard in the Robotaxi Space While Tesla is just about to enter the robotaxi market, some competitors like Alphabet and Baidu are already far ahead. Alphabet's Waymo has built a significant lead. Waymo is currently running commercial robotaxi services in four U.S. cities. The company offers over 250,000 paid rides per week, thanks to years of testing, experience, and strong partnerships. Alphabet has also committed to investing $5 billion in Waymo over the coming years. Baidu's Apollo Go is another major player. In China, Baidu operates a fleet of over 400 robotaxis in cities like Wuhan. Baidu is now preparing to expand its Apollo Go service into Europe, starting with Switzerland by the end of 2025. The company is also planning a launch in Turkey, further widening its global footprint. Like Waymo, Baidu has years of operational experience that give it an early edge. TSLA's Price Performance, Valuation and Estimates Shares of Tesla have lost around 19% year to date compared with the industry's decline of 22%. From a valuation standpoint, TSLA trades at a forward price-to-sales ratio of 10.02, way above the industry and its own 5-year average. It carries a Value Score of F. Tesla stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baidu, Inc. (BIDU): Free Stock Analysis Report Tesla, Inc. (TSLA): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report
